Results 251 to 260 of about 9,201,131 (312)

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Human Milk Biology: Illuminating the Path toward the Next Generation of Infant Formula. [PDF]

Adv Nutr
Bremer AA.
europepmc   +1 more source

Polymer Concepts in Cellular Function. [PDF]

Adv Sci (Weinh)
Yu M, Dhiman S, Dormann D, Gräter F, Luck K, Schmid F, Walther A, Lemke EA.   +7 more
europepmc   +1 more source

Comment on: Rectifying COPD management: a critical analysis of the global initiative for chronic obstructive lung disease strategy. [PDF]

ERJ Open Res
Semenzato U, Padrin Y, Previtero D, Tinè M, Bazzan E, Turato G.   +5 more
europepmc   +1 more source